norditropin nordiflex 10 mg/1.5 ml
novo nordisk a/s - somatropin - injeksjonsvæske, oppløsning i ferdigfylt penn - 10 mg/1.5 ml
actikerall 5 mg/ g / 100 mg/ g
almirall hermal gmbh - fluorouracil / salisylsyre - liniment, oppløsning - 5 mg/ g / 100 mg/ g
norditropin nordiflex 10 mg/1.5 ml
novo nordisk a/s - somatropin - injeksjonsvæske, oppløsning i ferdigfylt penn - 10 mg/1.5 ml
norditropin nordiflex 5 mg/1.5 ml
novo nordisk a/s - somatropin - injeksjonsvæske, oppløsning i ferdigfylt penn - 5 mg/1.5 ml
alacare 8 mg
photonamic gmbh & co. kg - 5-aminolevulinsyre - medisinert plaster - 8 mg
pamorelin 22.5 mg
institut produits synthèse (ipsen) ab - triptorelinembonat - pulver og væske til depotinjeksjonsvæske, suspensjon - 22.5 mg
sogroya
novo nordisk a/s - somapacitan - vekst - hypofysiske og hypotalamiske hormoner og analoger - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).
osurnia
dechra regulatory b.v. - betamethasone acetate, terbinafine, florfenicol - kortikosteroider og antiinfectives i kombinasjon - hunder - behandling av akutt otitis externa.
voxzogo
biomarin international limited - vosoritide - achondroplasia - legemidler til behandling av bein sykdommer - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
imcivree
rhythm pharmaceuticals netherlands b.v. - setmelanotide - fedme - antiobesity preparater, ekskl. diettprodukter - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.